REGENCOR INC
Los Altos, CA · Medtech · Private
Bioabsorbable collagen matrix patch containing recombinant human Follistatin-like 1 (rhFSTL1) for cardiac regeneration
- Grants
- $8.0M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 0 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling Epicardial Biopharmaceutical in the Diabetic Heart | $444,786 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling Epicardial Biopharmaceutical in the Diabetic Heart | $1,997,399 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enablingEpicardial Biopharmaceutical in the Diabetic Heart | $3,758,095 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling Epicardial Biopharmaceutical in the Diabetic Heart | $1,760,696 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1030 | ALIENBYTE Scientific Software Inc | — | — |
| 1031 | Limber Prosthetics, Inc. | — | $3.9M |
| 1032 | CAREBAND, INC. | — | — |
| 1033 | REGENCOR INC | — | — |
| 1034 | DESIGN CONCEPTS, INC | — | — |
| 1035 | VASOWATCH LLC | — | — |
| 1036 | Vita Imaging Inc. | — | $950K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Follistatin-like 1 (FSTL1) For Repairing Cardiac Tissueapplication
- Use Of Follistatin-like 1 (FSTL1) In Cardiometabolic Heart Failureapplication
- Methods Of Treating Dilated Cardiomyopathyapplication
- Follistatin-like 1 (FSTL1) For Repairing Cardiac Tissueapplication
- Methods Of Treating Dilated Cardiomyopathyapplication
- Use Of Follistatin-like 1 (FSTL1) In Cardiometabolic Heart Failureapplication
- Use Of Follistatin-like 1 (FSTL1) In Cardiometabolic Heart Failureapplication
- Use Of Follistatin-like 1 (FSTL1) In Cardiometabolic Heart Failure With Reduced Ejection Fractionapplication
- Epicardial-dervied Paracrine Factors For Repairing Cardiac Tissueapplication
- Follistatin-Like-1-Eluting or Expressing Device for Treatment of Heart Diseaseapplication
- Methods Of Treating Dilated Cardiomyopathyapplication
- Follistatin-like 1 (FSTL1) For Repairing Cardiac Tissueapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.